Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sangamo Therapeutics, Inc. (SGMO) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI‑generated summaries that help explain their contents. Sangamo is a genomic medicine company listed on the Nasdaq Capital Market, and its filings document clinical, regulatory, financial and listing‑related developments across its Fabry disease and neurology‑focused pipeline.
Investors can review Sangamo’s current reports on Form 8‑K, which the company uses to report material events. Recent 8‑Ks describe positive topline and updated data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST‑920) in Fabry disease, including mean annualized estimated glomerular filtration rate (eGFR) slopes and safety findings, as well as the FDA’s agreement to use eGFR slope as an endpoint for an accelerated approval pathway. Other 8‑Ks cover quarterly financial results, collaboration and license agreements, executive transitions and a Nasdaq notice granting additional time to regain compliance with the minimum bid price requirement.
Annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) provide more detailed information on Sangamo’s research and development expenses, general and administrative costs, cash and cash equivalents, and risk factors related to its genomic medicine programs, collaborations and capital needs. These filings also elaborate on the company’s description of its business as a neurology‑focused genomic medicine company and its reliance on investigational product candidates such as ST‑920, ST‑503 and ST‑506.
On this page, Stock Titan’s tools surface new SGMO filings from EDGAR in near real time and apply AI‑powered analysis to highlight key points, such as clinical endpoints referenced in 8‑Ks, updates on BLA preparation activities, or disclosures about Nasdaq listing compliance. Users can also locate proxy statements and other governance‑related documents to better understand Sangamo’s executive compensation plans and board‑level decisions, as referenced in its SEC filings. This combination of source documents and AI summaries is intended to make it easier to interpret complex regulatory language without replacing the need to read the original filings.
Sangamo Therapeutics reported that SVP and Chief Legal Officer Scott B. Willoughby received a grant of stock options covering 800,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.
These options were granted as compensation and do not represent an open-market purchase or sale. One quarter of the options will vest after one year from the grant date, with the remaining shares vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan.
Sangamo Therapeutics’ annual report highlights both scientific progress and severe financial strain. The company focuses on zinc finger–based genomic medicines for neurologic diseases, including ST-503 for chronic neuropathic pain and ST-506 for prion disease, plus a strong AAV capsid platform (STAC-BBB) licensed to major partners.
Sangamo reports positive Phase 1/2 data for its Fabry gene therapy isaralgagene civaparvovec, including favorable kidney function slopes and quality-of-life gains, and has begun a rolling BLA submission under the FDA’s Accelerated Approval pathway. However, management states there is substantial doubt about its ability to continue as a going concern, warning it needs substantial near-term funding and may have to cease operations or seek U.S. bankruptcy protection.
The company has received significant collaboration revenue and could earn large future milestones, but also notes ongoing Nasdaq listing noncompliance, potential delisting, high dilution risk, and continued operating losses with no approved products.
Sangamo Therapeutics reported mixed 2025 results, combining major clinical progress with significant financial strain. The company highlighted positive topline data from its registrational STAAR study in Fabry disease and is advancing a rolling Biologics License Agreement submission for gene therapy candidate ST-920 under the FDA’s Accelerated Approval pathway.
Sangamo repositioned itself as a clinical-stage neurology company, with Fast Track Designation for chronic neuropathic pain candidate ST-503 and ongoing development of prion disease program ST-506. It also entered a third neurology capsid license agreement, this time with Eli Lilly, and has raised over $130 million since the start of 2025 through license fees, milestones and equity financing.
Financially, 2025 revenue fell to $39.6 million from $57.8 million in 2024, mainly due to lower Genentech collaboration revenue, partly offset by new payments from Lilly and Pfizer. Full-year net loss widened to $122.9 million. Cash and cash equivalents declined to $20.9 million at year-end, and total stockholders’ equity moved to a deficit of $14.3 million. Sangamo believes its cash, plus early 2026 financing inflows, will fund operations into the third quarter of 2026, and its 2026 operating expense guidance is explicitly dependent on securing additional funding.
Sangamo Therapeutics senior executive reports share dispositions tied to RSU tax withholding. SVP and Chief Development Officer Nathalie Dubois-Stringfellow surrendered 2,063 common shares at $0.4725 per share on February 24, 2026 and 12,354 shares at $0.47 per share on February 25, 2026.
Both transactions were required to cover taxes on restricted stock units that had just vested under the company’s 2018 Equity Incentive Plan and were deemed dispositions to the company, not discretionary open‑market trades. After these transactions, she directly owns 678,711 common shares.
Sangamo Therapeutics President and CEO Sandy Macrae reported two required tax-withholding dispositions of common stock tied to vested restricted stock units. On February 24, 2026, 5,291 shares were surrendered at $0.4725 per share, and on February 25, 2026, 33,637 shares were surrendered at $0.47 per share. The footnotes state these transactions were made solely to cover mandatory tax obligations under the company’s equity incentive plan and were not discretionary open-market trades. After these transactions, Macrae directly held 1,907,656 shares of common stock.
Sangamo Therapeutics SVP and Chief Legal Officer Scott B. Willoughby reported mandatory tax-withholding share dispositions tied to restricted stock unit (RSU) vesting. On February 24, 2026, 1,650 common shares were surrendered at $0.4725 per share, and on February 25, 2026, 12,354 common shares were surrendered at $0.47 per share.
In both cases, the shares were delivered back to the company solely to cover tax liabilities upon RSU vesting under Sangamo’s 2018 Equity Incentive Plan and were not discretionary open-market trades. After these transactions, Willoughby directly owned 651,406 shares of Sangamo common stock.
Sangamo Therapeutics principal accounting officer Nikunj Jain reported two share dispositions tied to restricted stock unit (RSU) vesting and tax withholding. On February 24, 2026, 666 shares of common stock were surrendered at $0.4725 per share to satisfy mandatory tax obligations on vested RSUs.
On February 25, 2026, an additional 5,119 shares were surrendered at $0.47 per share for the same tax-withholding purpose under the company’s 2018 Equity Incentive Plan. These transactions are reported as dispositions to the company and are explicitly described as non-discretionary, not open-market trades.
Sangamo Therapeutics Head of Research & Technology Gregory D. Davis reported mandatory tax-related share dispositions tied to vesting restricted stock units. On February 24, 2026, 832 shares of common stock were surrendered at $0.4725 per share for required tax withholding. On February 25, 2026, an additional 5,119 shares were surrendered at $0.47 per share, also solely to cover tax obligations under the company’s 2018 equity incentive plan. These transactions are recorded as dispositions to the company for reporting purposes and are not discretionary open‑market trades. Following the later transaction, Davis directly owned 185,111 common shares.
Sangamo Therapeutics, Inc. entered into an underwritten public offering of 35,190,292 shares of common stock and pre-funded warrants for 17,787,033 shares, each paired with purchase warrants to buy a total of 52,977,325 shares. The combined offering prices are $0.4719 per common-share unit and $0.4619 per pre-funded warrant unit, with expected gross proceeds of approximately $25.0 million before fees, and closing expected on February 4, 2026, subject to customary conditions.
The pre-funded warrants are immediately exercisable at $0.01 per share with ownership caps up to 19.99%, while the purchase warrants become exercisable six months after issuance at $0.4719 per share for five and a half years, subject to a 4.99% ownership cap that can also be increased to 19.99%. In connection with the deal, Sangamo amended March 26, 2024 warrants held by the investor to reduce the exercise price on 23,809,523 shares from $1.00 to $0.4719 and extend their term to five and a half years from the offering’s closing.
Sangamo Therapeutics is offering 35,190,292 shares of common stock, pre-funded warrants for 17,787,033 shares, and purchase warrants for 52,977,325 shares. Securities are priced at $0.4719 per share and accompanying purchase warrant (or $0.4619 for a pre-funded warrant plus purchase warrant), yielding gross proceeds of about $24.8 million and estimated net proceeds of about $22.9 million before any warrant exercises.
The company plans to use the cash for working capital and general corporate purposes. Sangamo estimates cash and cash equivalents of approximately $20.9 million as of December 31, 2025 and, together with $2.0 million from its at-the-market program and this offering, expects funding only into the beginning of the third quarter of 2026.
The filing states there is substantial doubt about Sangamo’s ability to continue as a going concern even after this raise and notes active consideration of significant cost cuts and potential bankruptcy protection if additional capital or partnerships are not secured. The company also faces Nasdaq delisting risk due to its share price remaining below the $1.00 minimum bid requirement, with an extension to regain compliance by April 27, 2026.